Small RNA Drug Using mRNA Base Pairing for Cancer Cell Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for lung and pancreatic cancer are often ineffective at early stages and lack precision, leading to late diagnoses and poor prognosis, with a need for more targeted therapeutic approaches.
Innovation Solution
Development of small RNAs derived from traditional Chinese medicine that inhibit the activity of cancer cells, specifically targeting lung and pancreatic cancer cells, providing a precision medical treatment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional treatments (surgery, radiotherapy, chemotherapy) are used for lung and pancreatic cancer, then treatment coverage is broad, but treatment precision and effectiveness at early stages are insufficient
Solution Approach 1:
The patent segments the broad cancer treatment approach into specific targeted therapies. Small RNAs are designed to target specific cancer cell types (lung cancer, pancreatic cancer) through complementary base pairing with specific mRNA sequences, dividing the general treatment into precise, targeted interventions that address early-stage cancer with higher precision and effectiveness.
Solution Approach 2:
The patent applies local quality by creating treatments with site-specific action. The small RNA molecules are designed to bind specifically to target mRNA sequences in cancer cells, exerting their inhibitory effect only at the local level of cancer cell gene expression, thereby achieving precise treatment without affecting healthy tissues.
2Loss of time
If conventional treatments are applied, then treatment coverage is comprehensive, but early stage detection and intervention capability is limited
Solution Approach 1:
The patent implements preliminary action by enabling early-stage cancer intervention through highly specific molecular targeting. The small RNA therapy can be applied at early stages when cancer is more treatable, preventing progression to late stages. The specific molecular mechanism allows for early detection and intervention before cancer becomes advanced, improving prognosis by acting preliminarily rather than reactively.
3Adaptability or versatility
If broad-spectrum treatments are used, then applicability to various cancer types is achieved, but specificity to target cancer cells is reduced
Solution Approach 1:
The patent achieves universality through a modular small RNA design platform. The same basic small RNA mechanism can be adapted to target different cancer types by changing the sequence complementarity. This allows one therapeutic approach to be universally applicable across lung cancer, pancreatic cancer, and potentially other cancer types, while maintaining high specificity through sequence-specific binding to target mRNAs.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The small RNAs effectively suppress the activity of various cancer cell lines, including lung, pancreatic, prostate, breast, gastric, and colon cancer cells, offering a promising precision treatment option.
Implementation Method 1
a small RNA molecule, wherein the small RNA molecule targets cyclooxygenase-2 and comprises a core sequence GUUCGA
Data Source
AI summary
Provided is a small RNA drug for inhibiting the activity of cancer cells. Specifically, provided are an isolated nucleic acid molecule as shown in any one of SEQ ID NO: 1 to SEQ ID NO: 133, or an isolated nucleic acid molecule as shown in a sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, 96%, 97%, 98, and 99% sequence identity therewith, a vector, a host cell, and a pharmaceutical composition comprising same, and a use thereof in treatment of cancers.